New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcri

New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcriПодробнее

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRIПодробнее

The Four Levels of #ProstateCancer Treatment Intensity | #markscholzmd #alexscholz @ThePCRIПодробнее

Metastatic #ProstateCancer Treatment Case Study | #MarkScholzMD #AlexScholz #PCRIПодробнее

#ProstateCancer Diagnosis Over 80 Years Old | #MarkScholzMD #AlexScholz | #PCRIПодробнее

PSMA & Newly-Diagnosed #ProstateCancer | MarkScholzMD #AlexScholz #PCRIПодробнее

Does #ProstateCancer Tumor Size and Location Matter? | #MarkScholzMD #AlexScholz | #PCRIПодробнее

Advanced #ProstateCancer Treatments + Extended Q+A | #MarkScholzMD & #MarkMoyadMD #PCRIПодробнее

How Much Time Do You Have to Treat #ProstateCancer? | #MarkScholzMD #AlexScholz #PCRIПодробнее

How PSA Responds to #ProstateCancer Treatment | #MarkScholzMD #AlexScholz #PCRIПодробнее

Learn About PARP Inhibitors For #ProstateCancer #Talzenna #AkeegaПодробнее

Treating Side Effects of Hormone Therapy | #MarkScholzMD #AlexScholz #PCRIПодробнее

Osteoporosis: Treatments & Preventing Fractures | #MarkScholzMD #AlexScholz #PCRIПодробнее

#ProstateCancer Treatments: Earlier Rather Than Later? | #markscholzmd #alexscholz @ThePCRIПодробнее

2022 Recap: New Treatments and Approaches in #prostatecancer | #markscholzmd | PCRIПодробнее

TALAVE: induction talazoparib with PARP inhibition in breast cancerПодробнее

Talazoparib plus enzalutamide shows improvement in PFS over SOC in first-line HRR mCRPCПодробнее

Do You Know Your Testosterone Levels? | Symptoms & Testing | #MarkScholzMD #AlexScholz #PCRIПодробнее

3+4=7 #ProstateCancer | Active Surveillance vs. Focal Therapy | #MarkScholzMD #AlexScholz #PCRIПодробнее